ADC Therapeutics
ADCT • NYSE
ADC Therapeutics is a biotechnology company in the healthcare sector trading on NYSE, led by CEO Ameet Mallik, with a market cap of $470.1M.
CEOAmeet Mallik
Next Earnings
Upcoming earnings announcement for ADC Therapeutics
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.24
Revenue Estimate
$19.9M
Earnings History
Past 12 earnings reports for ADC Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | Q4 2025 | -$0.09Est: -$0.29 | +69.0% | $23.1MEst: $21.0M | +9.6% |  10-K |
| Nov 10, 2025 | Q3 2025 | -$0.19Est: -$0.38 | +50.0% | $16.4MEst: $16.5M | -0.5% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.25Est: -$0.36 | +30.6% | $18.8MEst: $18.2M | +3.5% | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.22Est: -$0.38 | +42.1% | $23.0MEst: $18.2M | +26.9% | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.25Est: -$0.35 | +28.6% | $16.9MEst: $19.7M | -14.0% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.28Est: -$0.39 | +28.2% | $18.5MEst: $18.5M | +0.0% | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$0.25Est: -$0.44 | +43.2% | $17.4MEst: $18.9M | -8.0% | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.38Est: -$0.56 | +32.1% | $18.1MEst: $18.2M | -0.9% | 10-Q |
| Mar 13, 2024 | Q4 2023 | -$0.97Est: -$0.50 | -94.0% | $16.8MEst: $15.3M | +9.5% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.41Est: -$0.63 | +34.9% | $14.5MEst: $16.0M | -9.4% | — |
| Aug 8, 2023 | Q2 2023 | -$0.37Est: -$0.44 | +15.9% | $19.3MEst: $34.8M | -44.5% | — |
| May 9, 2023 | Q1 2023 | -$0.53Est: -$0.67 | +20.9% | $19.0MEst: $20.1M | -5.5% | — |